Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.63 |
| ▸ | AKT2 | P31751 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137952 | 0.91 | NCF1 (0.56) | NCF1ADRB2AKT2KCNH2SSTR2 | |
| SCHEMBL28251236 | 0.84 | NCF1 (0.63) | NCF1ADRB2AKT2KCNH2F10 | |
| SCHEMBL22755427 | 0.84 | ADRB2 (0.63) | NCF1ADRB2KCNH2CNR2PDGFRB | |
| SCHEMBL29722401 | 0.84 | ADRB2 (0.58) | NCF1ADRB2AKT2KCNH2F10 | |
| SCHEMBL18980471 | 0.84 | ADRB2 (0.58) | NCF1ADRB2AKT2KCNH2F10 | |
| SCHEMBL30404498 | 0.82 | PBK (0.61) | NCF1ADRB2KCNH2ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL18979970 | 0.82 | ADRB2 (0.57) | NCF1ADRB2AKT2KCNH2F10 | |
| Hydrochloric Acid SCHEMBL18980776 | 0.82 | ADRB2 (0.57) | NCF1ADRB2AKT2KCNH2F10 | |
| Hydrochloric Acid SCHEMBL29722226 | 0.82 | ADRB2 (0.57) | NCF1ADRB2AKT2KCNH2F10 | |
| SCHEMBL14515644 | 0.82 | NCF1 (0.73) | NCF1ADRB2KCNH2AKT1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021076448-A1 | SOMATOSTATIN MODULATORS FOR TREATING PITUITARY ADENOMAS | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-22 | — | — | WO | claimed |
| EP-2066654-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | Bayer Schering Pharma AG (DE) | 2009-06-10 | — | — | EP | claimed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | claimed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2008028691-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | claimed |
| US-20210087165-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2021-03-25 | — | — | US | disclosed |
| WO-2021011641-A1 | CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10889561-B2 | Process of making somatostatin modulators | Crinetics Pharmaceuticals, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200048219-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2020-02-13 | — | — | US | disclosed |
| US-10464918-B2 | Process of making somatostatin modulators | Crinetics Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190218202-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2019-07-18 | — | — | US | disclosed |
| EP-2066654-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | Bayer Schering Pharma AG (DE) | 2009-06-10 | — | — | EP | disclosed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008028691-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464918-B2 | Process of making somatostatin modulators | SSTR5, SSTR4, SSTR2 | NCF1 3102/4885ADRB2 224/4885AKT2 1922/4885 |
| US-20190218202-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | NCF1 3102/4885ADRB2 224/4885AKT2 1922/4885 |
| US-20210087165-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | NCF1 3102/4885ADRB2 224/4885AKT2 1922/4885 |
| US-20200048219-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | NCF1 3102/4885ADRB2 224/4885AKT2 1922/4885 |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | PTGER2, PTGER1, PTGDR2 | NCF1 2439/4885ADRB2 71/4885AKT2 2349/4885 |
| US-10889561-B2 | Process of making somatostatin modulators | SSTR5, SSTR4, SSTR2 | NCF1 3102/4885ADRB2 224/4885AKT2 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.